Finding advances search for cure other than liver transplantation
A protein modified to increase the amount of time it circulates in the bloodstream appears to reverse liver fibrosis and cirrhosis in rats, according to results of a study led by Johns Hopkins researchers.
The investigators say the findings, reported ahead of print in the March 3 early view edition of Hepatology, advance the search for a potential cure for the thousands of patients worldwide living with these incurable diseases. At present, there is little effective treatment and no cure other than liver transplantation, which carries its own risks and often fails.
“Our findings demonstrate that the damaging effects of liver cirrhosis in laboratory rats can be effectively treated, and perhaps even reversed, using a protein therapeutic that has been modified to enhance its activity through site-specific conjugation of a polymer that greatly enhances its residence time in the body,” says senior author Justin Hanes, Ph.D., director of the Center for Nanomedicine at the Wilmer Eye Institute at Johns Hopkins. “This approach has tremendous potential to help people with this devastating condition and may also be helpful to the millions of patients with other diseases where fibrosis plays an important role.”
Liver fibrosis and its more severe form, cirrhosis, are caused by scar tissue that forms in the liver that is usually induced by chronic alcohol abuse, infections and autoimmune diseases. The progressive stiffening of the liver, a hallmark of the disorders, occurs when a type of liver cell known as the hepatic stellate cell is “activated” and overproduces the stringy network of proteins called the extracellular matrix that binds cells together.
Being able to turn cirrhosis around, especially in its late stages, would be a great boon, says Seulki Lee, Ph.D., assistant professor in the Department of Radiology and Radiological Science at the Johns Hopkins University School of Medicine. “That’s because liver fibrosis and cirrhosis can be asymptomatic for decades,” Lee says. “Many patients only seek treatment when their disease becomes very advanced, at which point liver transplant is their only option.”
Lee cautions, however, that his team’s work is years from any possible application to patients.
Scientists have known for more than a decade that a protein called tumor necrosis factor-related apoptosis-inducing ligand — TRAIL, for short — can specifically kill activated hepatic stellate cells that overproduce the extracellular matrix, sparing healthy cells in the liver. However, Lee explains, TRAIL has thus far proven unsuccessful for clinical use because in animal studies, enzymes in the bloodstream quickly degrade it before it has time to work.
Seeking a way to extend TRAIL’s half-life, or the time that it remains intact in the bloodstream, Lee and his colleagues coated TRAIL with polyethylene glycol (PEG), a synthetic polymer that’s widely used as a preservative, lubricant and ingredient in skin creams, and is already being used to extend the bloodstream life of a handful of drugs that treat neutropenia, hemophilia and rheumatoid arthritis.
Lee says initial experiments showed that this “PEGylated” TRAIL had a half-life of between eight and nine hours in monkeys, compared to less than 30 minutes for the unmodified protein. When the scientists intravenously dosed rats that had liver fibrosis with the modified TRAIL for 10 days, the animals’ activated hepatic stellate cells died off. By fighting these bad cells, signs of fibrosis began to diminish. Further investigation showed that multiple genes associated with fibrosis had reduced activity, and the proteins produced by these genes faded away.
Findings were similar in rats with advanced cirrhosis, Lee says. Additionally, when the researchers examined the rodents’ liver tissue under a microscope, they found that animals treated with PEGylated TRAIL had fewer deposits of collagen and other extracellular matrix proteins, offering some evidence that the disease had actually been reversed.
Further experiments showed that PEGylated TRAIL selectively killed human-activated hepatic stellate cells growing in petri dishes while leaving normal liver cells unharmed, suggesting that findings in these animal models could apply to damaged human livers with limited toxicity concerns.
Lee says the research team hopes to develop PEGylated TRAIL for clinical trials in human patients in the next two years. He adds that some preliminary data suggest that the modified protein could also treat other fibrotic diseases as well, such as pancreatic or lung fibrosis, which also have no effective treatment.
“Eventually,” Lee says, “we might be able to develop PEGylated TRAIL into a universal anti-fibrotic agent that can treat many different conditions.”
Learn more: Modified protein reverses cirrhosis in lab rats
The Latest on: Protein therapeutic
via Google News
The Latest on: Protein therapeutic
- IPO Lockup Expiration Alert: Nurix Therapeutics (NRIX)on January 19, 2021 at 8:28 pm
(RTTNews) - The lockup period of San Francisco, California-based Nurix Therapeutics (NRIX) expires tomorrow , i.e., January 20, 2021. Nurix ...
- Mapping antibody reactivity in COVID-19 patients by using multi-coronavirus protein microarrayon January 19, 2021 at 5:59 pm
In an exciting, state-of-the-art study currently available on the medRxiv* preprint server, US researchers created a multi-coronavirus protein microarray containing full-length proteins, peptide ...
- Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Sees Large Increase in Short Intereston January 19, 2021 at 4:41 pm
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 1,140,000 shares, a ...
- Aclaris Therapeutics' stock skyrockets 220% on positive data for potential arthritis treatmenton January 19, 2021 at 4:20 pm
More than 113 million shares of the company traded on Tuesday. By comparison, 295,200 shares changed hands on Friday, according to Yahoo Finance. Aclaris (NASDAQ: ACRS) announced positive phase 2 ...
- Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Proteinon January 19, 2021 at 2:05 pm
Dr. Robert Allen, Senior Vice President, Antiviral and Oncolytic Immunotherapy Development at Sorrento and Chief Scientific Officer of SmartPharm Therapeutics, will be presenting data from the ...
- Protein Therapeutics Market on Position to Reach $217,591 Million by 2023on January 18, 2021 at 10:37 am
Pharmaceutical companies have streamlined drug discovery and development through adoption of protein therapeutics Therapeutic proteins have immensely aided in target based treatment for chronic ...
- New therapeutic approach enables functional recovery after spinal cord injury in miceon January 16, 2021 at 11:12 am
Using gene therapy, a research team has succeeded for the first time in getting mice to walk again after a complete cross-sectional injury. The nerve cells produced the curative protein themselves.
- Worldwide Protein Therapeutics Industry to 2026 - Favorable Reimbursement Laws are Driving Growth - ResearchAndMarkets.comon January 15, 2021 at 8:42 am
ResearchAndMarkets.com The “Protein Therapeutics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026” report has been added to ResearchAndMarkets.com’s offering. The report ...
- Global Protein Therapeutics Market (2020 to 2026) - Industry Analysis, Trends, Market Size, and Forecastson January 14, 2021 at 9:08 am
The "Protein Therapeutics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has ...
- Kymera Therapeutics Is A Protein Degrading Pioneer With A Triple-Figure Share Price In Waitingon January 14, 2021 at 8:09 am
Kymera is one of several biotechs pioneering targeted protein degradation science and technology - removing unwanted proteins by marking them for destruction by the proteasome. The company IPOd in ...
via Bing News